Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%.

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

The FDA has issued warnings regarding potential cardiac risks, specifically myocarditis and pericarditis, associated with the ...

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

The Food and Drug Administration department of the US has updated its warning about rare heart risk associated with to ...

The leader of the Kennedy-appointed vaccine panel said it will reconsider the government’s recommendations for childhood ...

Australia's vaccination rates against COVID and influenza are below ideal figures, but could a future innovation be able to ...

The FDA has approved its requested updated versions of expanded warning labels for COVID-19 vaccines. As Healio previously ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...

After a tumultuous year of layoffs and strategic shifts, a Philadelphia biotech company has found a lifeline through a merger ...

The FDA has approved required updates to the labeling of Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines to include revised warnings about the risk of myocarditis and pericarditis ...